Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Venous thromboembolism and bleeding in advanced melanoma: a propensity-matched cohort analysis comparing first-line immunotherapy and targeted therapy.
Journal: Research and practice in thrombosis and haemostasis
Published: June 24, 2026
Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.
Journal: Clinical lung cancer
Published: January 20, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: January 15, 2026
Lung cancer with EGFR PACC mutations: a practical review of available treatment options and novel therapies on the horizon.
Journal: Translational lung cancer research
Published: January 14, 2026
Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results.
Journal: Journal of clinical pathology
Published: February 03, 2025
Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 08, 2024
Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2024
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.
Journal: JTO clinical and research reports
Published: October 24, 2023
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
Journal: Translational lung cancer research
Published: February 10, 2023
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 15, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Journal: Expert review of anticancer therapy
Published: June 14, 2022
Last Updated: 09/26/2026